Azitra, Inc. (AZTR) - Form 8-K Summary
Business Context and Reporting Period
Azitra, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 6, 2025, regarding events occurring on February 5 and February 6, 2025. The Company is an emerging growth company with its principal executive offices in Branford, Connecticut.
Key Financial Metrics and Transaction Details
This filing reports a capital raise transaction rather than standard operating financial metrics. The filing text does not provide revenue, profit, cash flow, margins, or debt figures.
- Equity Issuance: Closed an offering of 2,495,518 shares of Common Stock to certain investors.
- Warrant Issuance: Issued warrants to purchase up to 2,245,967 shares of Common Stock.
- Warrant Terms: Exercisable starting six months and one day after issuance. Exercise price is the greater of book value or market value per NYSE American Rules.
- Future Financing Rights: Investors granted a two-year right to participate in future financings up to 50% of the aggregate amount.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement (SPA) dated February 4, 2025, and amended on February 5, 2025. Concurrently, a Letter Agreement was executed on February 6, 2025, establishing the warrant issuance and future financing participation rights. The Company is obligated to file a registration statement for the warrant shares and use best efforts to make it effective within six months of the Letter Agreement closing.
Outlook, Risks, and Contingencies
The securities were sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and/or Regulation D. The filing notes the requirement to register the underlying shares of the warrants within six months. No specific management commentary on operational outlook or risks beyond the transaction terms is provided in this text.
Investor Verification Checklist
- Verify the final closing price per share for the 2,495,518 shares issued to determine total capital raised.
- Review the "Form of Warrant" (Exhibit 4.1) for specific definitions of "book value" and "market value" used to calculate the exercise price.
- Confirm the timeline for the registration statement filing required for the warrant shares.
- Assess the potential dilution impact of the 2,245,967 warrant shares and the 50% future financing participation right.